Access Bio, Inc. (KOSDAQ:950130)

South Korea · Delayed Price · Currency is KRW

2,230.00

-60.00 (-2.62%)

Jul 1, 2026, 3:30 PM KST

-58.40% (1Y)

Market Cap	80.55B -53.2%
Revenue (ttm)	14.94B -84.8%
Net Income	-83.17B
EPS	-2,364.02
Shares Out	35.17M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	34,097
Open	2,290.00
Previous Close	2,290.00
Day's Range	2,215.00 - 2,340.00
52-Week Range	2,085.00 - 5,620.00
Beta	0.21
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 14, 2026

About Access Bio

Access Bio, Inc. engages in the research, development, and manufacture of in vitro rapid diagnostic tests, immunochemical diagnostics, biosensors, and molecular diagnostic products worldwide. The company provides Covid-19 detection kits, which are tests for assessing the current or past presence of SARS-CoV-2.; rapid diagnostic tests, suitable for preliminary diagnosis or emergency medical screening in medical facilities with limited resources; analyzers, designed to measure different chemicals and other characteristics in biological samples; a... [Read more]

Industry Medical - Specialties

Sector Healthcare

Founded 2002

Employees 101

Stock Exchange KOSDAQ

Ticker Symbol 950130

Full Company Profile

Financial Performance

In 2025, Access Bio's revenue was 31.26 billion, a decrease of -72.21% compared to the previous year's 112.46 billion. Losses were -82.12 billion, 23525.9% more than in 2024.

Financial Statements